Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐CoV‐2 infection

Documenti analoghi

• Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS‐CoV‐2: AGILE CST‐3a/b
  di: B. Thompson, et al.
  Pubblicazione: (2025)
• Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration
  Pubblicazione: (2024)
• Insights on multi‐spectroscopic approaches for estimating the in vitro binding of favipiravir with adenine nucleotide
  di: Reem N. El Gammal, et al.
  Pubblicazione: (2024)
• Failure of favipiravir to treat chronic norovirus infection in a kidney‐transplant patient
  di: Amandine Darres, et al.
  Pubblicazione: (2024)
• Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6
  Pubblicazione: (2024)